Wegovy and Heart Disease: What UK Patients Should Know
If you are living in the UK and managing weight alongside cardiovascular health, understanding the link between Wegovy and heart disease is crucial. This guide explains how the medication works, the latest official MHRA approvals, and how it supports patients with existing cardiovascular conditions.
Medical Disclaimer: Wegovy does not treat heart disease directly, nor is it a cure. It is a prescription medicine that must be prescribed by a qualified healthcare provider alongside a reduced-calorie diet and increased physical activity. Speak to your doctor to determine if it is clinically appropriate for you.
What is the Link Between Wegovy and Heart Disease?
The term “cardiovascular disease” (CVD) includes a range of conditions that affect the heart or blood vessels, such as heart attacks and strokes. These conditions are often closely linked to obesity, poor diet, and other lifestyle factors.
Wegovy® (semaglutide) is a GLP-1 receptor agonist originally approved in the UK for weight loss. However, following new clinical evidence, it has been proven to reduce the risk of major cardiovascular events in people who already have established heart disease and a BMI of 27 kg/m² or higher.
Wegovy and Heart Disease: UK Approval & Clinical Evidence
Wegovy is the first weight-loss drug in the UK licensed specifically for the prevention of serious cardiovascular events in people living with cardiovascular disease and excess weight.
As of 23 July 2024, the UK’s MHRA officially approved Wegovy to help prevent cardiovascular death, non-fatal heart attacks, and non-fatal strokes in specific at-risk patients.
The approval was based on an international trial of over 17,600 adults with pre-existing cardiovascular disease. Participants were monitored over roughly five years.
In the trial, 6.5% of patients on Wegovy had a major cardiovascular event compared to 8% on a placebo. This represents a statistically significant 20% relative reduction in risk.
Crucially, these results were observed in patients without diabetes, giving a clear picture of Wegovy’s positive effects on heart health separate from blood sugar control.
How Wegovy Supports Cardiovascular Health
Semaglutide works by mimicking the GLP-1 hormone, which plays a critical role in controlling appetite, blood sugar, and digestion. These combined effects support sustained weight loss, which eases pressure on the heart and blood vessels.
1. Appetite Control
It acts on the brain to help you feel full sooner and for longer, significantly reducing hunger.
2. Digestion
It slows the emptying of the stomach, which contributes to prolonged satiety after meals.
3. Blood Sugar
It helps lower blood sugar levels after eating, improving overall metabolic function.
4. Administration
Taken as a once-weekly injection using a pre-filled pen, alongside a reduced-calorie diet and exercise.
Wegovy and Heart Disease: Safety Profile and Next Steps
Like all medications, Wegovy can cause side effects. The most common gastrointestinal side effects are usually mild and may improve over time as your body adjusts to the medication.
- Nausea and vomiting
- Diarrhoea
- Constipation
Reporting Side Effects: If you experience any severe or persistent side effects, speak to your GP, pharmacist, or prescribing clinician immediately. In the UK, you can also report safety concerns directly through the official MHRA Yellow Card Scheme.
In Summary: Wegovy and Heart Disease
For people in the UK living with both excess weight and cardiovascular disease, Wegovy now offers a new, evidence-based option to reduce the risk of serious heart events. While it isn’t a cure, it may play a key role in long-term heart health when used alongside healthy lifestyle changes, ongoing medical support, and checking UK Wegovy pricing for long-term affordability.
